Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer J ; 19(2): 147-50, 2013.
Article in English | MEDLINE | ID: mdl-23528723

ABSTRACT

The robotic approach to hepatic resection has evolved because of advances in laparoscopy and digital technology and based on the modern understanding of hepatic anatomy. Robotic technology has allowed for the development of a minimally invasive approach, which is conceptually similar to the open approach. The major differences are improved visualization and smaller incisions without a haptic interface. As a result, the operative strategy is reliant on visual cues and knowledge of hepatic surgical anatomy. Development of a robotic liver resection program ideally occurs in the setting of a comprehensive liver program with significant experience in all aspects of surgical liver care.


Subject(s)
Hepatectomy/methods , Liver Neoplasms/surgery , Surgery, Computer-Assisted/methods , Dissection/methods , Humans , Intraoperative Care , Liver/physiopathology , Liver/surgery , Liver Neoplasms/diagnostic imaging , Robotics/methods , Treatment Outcome , Ultrasonography
2.
Microsurgery ; 23(5): 432-6, 2003.
Article in English | MEDLINE | ID: mdl-14557996

ABSTRACT

We studied nonviral delivery, expression, and the effect of the human interleukin-10 (Hu IL-10) gene on the rat model of heterotopic auxiliary liver transplantation (HALT). Two previous pilot studies showed remarkable expression of the Hu IL-10 gene in donor and recipient rats, and a decreasing effect of acute rejection in certain cases. In this study, we focused on the efficacy of Hu IL-10 gene expression to decrease acute rejection compared with cyclosporine A (CyA) in a HALT model. Three study groups and one control group were designed. Each group consisted of 6 DA donor and 6 Lewis recipient rats, which underwent HALT. In the control group, donors and recipients were not treated at all. In group II, recipients were treated with one dose of CyA. In group III, donors were treated with Hu IL-10 plasmid. In group IV, donors were treated with Hu IL-10 plasmid, and recipients were treated with one dose of CyA. Rejection was established by histopathology: it revealed 100% rejection in control and 33.3% rejection in study groups II, III, and IV. Human IL-10 gene expression prevented acute rejection with the same efficacy as CyA in the HALT model in rats.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Gene Expression/immunology , Genetic Therapy/methods , Graft Rejection/prevention & control , Interleukin-10/administration & dosage , Liver Transplantation/immunology , Acute Disease , Adjuvants, Immunologic/genetics , Animals , Cyclosporine/administration & dosage , Female , Genetic Vectors/immunology , Graft Rejection/immunology , Humans , Immunosuppressive Agents/administration & dosage , Interleukin-10/genetics , Interleukin-10/immunology , Liver Transplantation/methods , Male , Models, Animal , Rats , Rats, Inbred Lew
3.
Diabetes ; 51(12): 3435-9, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12453897

ABSTRACT

Human islet expansion in monolayer culture leads to loss of function and senescence. By maintaining the 3-D configuration of islets in fibrin gels, it is feasible to expand beta-cells in response to hepatocyte growth factor (HGF) while preserving physiologic glucose responsiveness both in vitro and in vivo after transplantation into nude mice. Islets were cultured free floating with or without growth factors and nicotinamide and in fibrin gels with the same conditions. Proliferation was observed only in islets cultured in fibrin gels and the cocktail; total insulin increased by threefold, with a concomitant increase in beta-cell mass by morphometry. Insulin release after glucose challenge was also preserved. Islets in fibrin gels gave rise in vivo to large grafts rich in insulin and glucagon, and grafts from free-floating islets were smaller with fewer endocrine cells. Circulating human C-peptide levels were higher than in the mice receiving free-floating islets. In summary, fibrin allows for HGF-mediated cell proliferation while preserving glucose responsiveness in an environment that preserves cell-cell contacts. Limited islet ex vivo expansion under these conditions may improve recipient-donor tissue ratios to equal the functional results of whole-organ transplants.


Subject(s)
Hepatocyte Growth Factor/pharmacology , Islets of Langerhans/cytology , Islets of Langerhans/physiology , Animals , Cell Division/drug effects , Cell Survival/drug effects , Cells, Cultured , Feasibility Studies , Fibrin/pharmacology , Gels , Humans , Insulin/metabolism , Mice , Mice, Nude , Transplantation, Heterologous
SELECTION OF CITATIONS
SEARCH DETAIL
...